Seasickness Clinical Trial
Official title:
Seasickness Susceptability and Vestibular Time Constant
Verified date | November 2022 |
Source | Medical Corps, Israel Defense Force |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Participants were selected from the military navy crewmembers prior to commencing of active sailing. A vestibular time constant was calculated based on velocity step testing on a rotatory chair at baseline, 3 months and 6 month following active sailing duty. A seasickness questionnaire (WIKER) was completed during follow-up visits. study participants were divided to three groups based on WIKER score - susceptible , non-susceptible and habituating. Vestibular time constant was compared between study groups.
Status | Completed |
Enrollment | 67 |
Est. completion date | July 26, 2020 |
Est. primary completion date | January 26, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 20 Years |
Eligibility | Inclusion Criteria: - healthy male Navy sailors in basic training Exclusion Criteria: - History of hearing loss - Otoscopic findings of ear pathology - An implanted electrode - A finding of vestibulopathy upon otoneurological examination - - Discontinuation of active sailing for any reason during study follow-up - Withdrawal of informed consent. |
Country | Name | City | State |
---|---|---|---|
Israel | Israeli Naval Medical Institute | Haifa |
Lead Sponsor | Collaborator |
---|---|
Medical Corps, Israel Defense Force |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 6 month follow up vestibular time constant measurement. | vestibular time constant in seconds is the measurement of decline in maximal slow phase velocity of eye movement during nystagmus to 37% of initial value produced by abrupt acceleration and declarations in a rotatory chair - step velocity protocol. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04482985 -
Meclizine Plasma Levels in Responders and Non-responders
|
Phase 4 | |
Completed |
NCT05004818 -
Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness
|
N/A |